Kristin Poage, APRN
Nurse Practitioner · Topeka, KSNPI 1811329774
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 193 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $935, 2.6 times the $362 reported in 2021. Among nurse practitioner clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$471
- Novo Nordisk$451
- Lilly USA, LLC$350
- AbbVie$349
- Pfizer$216
- Amgen$213
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,444100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 11 | $471 |
| Novo Nordisk | 33 | $451 |
| Lilly USA, LLC | 19 | $350 |
| AbbVie | 18 | $349 |
| Pfizer | 15 | $216 |
| Amgen | 15 | $213 |
| GSK | 9 | $146 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $105 |
| Dexcom, Inc. | 5 | $103 |
| Merck | 4 | $71 |
| Boehringer Ingelheim | 5 | $71 |
| Irhythm Technologies, Inc. | 3 | $70 |
| Eisai Inc. | 3 | $69 |
| Dynavax Technologies Corporation | 5 | $68 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $62 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Melinta Therapeutics, LLC | 3 | $47 |
| Viiv Healthcare Company | 2 | $46 |
| Corium, LLC | 3 | $44 |
| Abbott | 3 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $36 |
| Johnson & Johnson | 2 | $34 |
| Myriad Genetic Laboratories, Inc. | 2 | $32 |
| Biogen | 2 | $31 |
| Exact Sciences | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Neurelis, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Organon | 1 | $12 |
| Mylan Specialty L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,444 in reported general payments places this provider in the 90th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $59,845 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $35,614 |
| MyrbetriqMirabegron | 31 | $21,573 |
| JardianceEmpagliflozin | 14 | $19,094 |
| TradjentaLinagliptin | 19 | $17,870 |
| TrulicityDulaglutide | 14 | $17,292 |
| EliquisApixaban | 25 | $16,765 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,174 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $6,692 |
| Atorvastatin Calcium | 367 | $2,918 |
| Levothyroxine Sodium | 369 | $2,846 |
| Gabapentin | 197 | $2,703 |
| Omeprazole | 266 | $2,656 |
| SynthroidLevothyroxine Sodium | 23 | $2,600 |
| Duloxetine Hcl | 127 | $2,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $451 | $59,84561 claims |
| Boehringer IngelheimJardiance, Tradjenta | $71 | $36,96433 claims |
| GSKTrelegy Ellipta | $146 | $35,61450 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $21,57331 claims |
| Lilly USA, LLCTrulicity | $350 | $17,29214 claims |
| PfizerEliquis | $216 | $16,76525 claims |
| AbbVieSynthroid | $349 | $2,60023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Topeka
- Gary GrafTopeka$726K
- Shannon GreggTopeka$140K
- Kelli BradburyTopeka$20K
- Laura WelbornTopeka$8K
- Alexandra HeerenTopeka$8K
- Amie WunderTopeka$8K
- Jayda RuppTopeka$7K
- Lora UtechTopeka$6K
- Anna ShortRoeland Park$215K
- Morteza RabiiOverland Park$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.